妊娠前遺伝子スクリーニング・サービス世界市場の見通し：詳細分析、予測(～2031年)

当レポートは、妊娠前遺伝子スクリーニング・サービス (Pre-Pregnancy Genetic Screening Service) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

• 概要 妊娠前遺伝子スクリーニング・サービス: 定義、特性、主要属性
• 市場セグメント：タイプ別
  • 世界の妊娠前遺伝子スクリーニング・サービス 市場規模：タイプ別, 2020 VS 2024 VS 2031
  • Single Disease Screening
  • Whole Genome Screening
• 市場セグメント：アプリケーション別
  • 世界の妊娠前遺伝子スクリーニング・サービス 市場規模：用途別, 2020 VS 2024 VS 2031
  • Medical and Health Institutions
  • Research and Educational Institutions
  • Others
• 前提条件と制限
• 調査目的
• 対象期間

第2章 レポート概要

• 世界の妊娠前遺伝子スクリーニング・サービスの収益 推定および予測 2020-2031
• 世界の妊娠前遺伝子スクリーニング・サービス 収益：地域別
  • 収益比較: 2020 VS 2024 VS 2031
  • 収益実績と予測 地域別 (2020-2031)
  • 世界の収益市場シェア 地域別 (2020-2031)
  • 新興市場: 成長要因と投資動向

第3章 企業間の競争

• 世界の妊娠前遺伝子スクリーニング・サービス 企業の収益ランキングと収益性
  • 世界の収益 (価格) ：競合別 (2020-2025)
  • 世界の主要企業の収益ランキング (2023 vs. 2024)
  • 収益ベースのTierセグメンテーション (Tier 1, Tier 2, and Tier 3)
  • 売上高総利益：トップ企業別 (2020 VS 2024)
• 世界の妊娠前遺伝子スクリーニング・サービス 企業本社とサービス拠点
• 主要製品タイプ 市場規模：企業別
  • Single Disease Screening Market Size by Players
  • Whole Genome Screening Market Size by Players
• 世界の妊娠前遺伝子スクリーニング・サービス 市場集中と力学
  • 世界の市場集中 (CR5 and HHI)
  • 新規参入／イグジットの影響分析
  • 戦略的な動き: M&A、事業拡大, 研究開発投資

第4章 世界の製品セグメンテーション分析

• 世界の妊娠前遺伝子スクリーニング・サービス 収益動向 タイプ別
  • 世界の収益実績と予測 タイプ別 (2020-2031)
  • 世界の収益市場シェア：タイプ別 (2020-2031)
• 主要製品の属性と差別化
• サブタイプの力学: 成長リーダー、収益性、リスク
  • 高成長な特定分野と採用ドライバー
  • 収益ホットスポットとコストドライバー
  • 代替品の脅威

第5章 世界の下流アプリケーション分析

• 世界の妊娠前遺伝子スクリーニング・サービス 収益：用途別
  • 世界の実績al andの収益予測：用途別 (2020-2031)
  • の収益市場シェア：用途別 (2020-2031)
  • 高成長アプリケーション識別
  • 新興アプリケーションのケーススタディ
• 下流 顧客分析
  • トップ顧客 地域別
  • トップ顧客 用途別

第6章 北米

• 北米の市場規模 (2020-2031)
• 北米の主要企業 収益 2024年
• 北米の妊娠前遺伝子スクリーニング・サービス 市場規模：タイプ別 (2020-2031)
• 北米の妊娠前遺伝子スクリーニング・サービス 市場規模：用途別 (2020-2031)
• 北米の成長促進要因と市場障壁
• 北米の妊娠前遺伝子スクリーニング・サービス 市場規模：国別
  • 北米の収益動向：国別
  • US
  • カナダ
  • メキシコ

第7章 欧州

• 欧州の市場規模 (2020-2031)
• 欧州の主要企業 収益 2024年
• 欧州の妊娠前遺伝子スクリーニング・サービス 市場規模：タイプ別 (2020-2031)
• 欧州の妊娠前遺伝子スクリーニング・サービス 市場規模：用途別 (2020-2031)
• 欧州の成長促進要因と市場障壁
• 欧州の妊娠前遺伝子スクリーニング・サービス 市場規模：国別
  • 欧州の収益動向：国別
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • ロシア

第8章 アジア太平洋地域

• アジア太平洋地域 市場規模 (2020-2031)
• アジア太平洋地域 主要企業 収益 2024年
• アジア太平洋地域 妊娠前遺伝子スクリーニング・サービス 市場規模：タイプ別 (2020-2031)
• アジア太平洋地域 妊娠前遺伝子スクリーニング・サービス 市場規模：用途別 (2020-2031)
• アジア太平洋地域 成長促進要因と市場障壁
• アジア太平洋地域 妊娠前遺伝子スクリーニング・サービス 市場規模：地域別
  • アジア太平洋地域 収益動向 地域別
• 中国
• 日本
• 韓国
• オーストラリア
• インド
• 東南アジア
  • インドネシア
  • ベトナム
  • マレーシア
  • フィリピン
  • シンガポール

第9章 中南米

• 中南米 市場規模 (2020-2031)
• 中南米 主要企業 収益 2024年
• 中南米 妊娠前遺伝子スクリーニング・サービス 市場規模：タイプ別 (2020-2031)
• 中南米 妊娠前遺伝子スクリーニング・サービス 市場規模：用途別 (2020-2031)
• 中南米 投資機会と主な課題
• 中南米 妊娠前遺伝子スクリーニング・サービス 市場規模：国別
  • 中南米 収益動向：国別 (2020 VS 2024 VS 2031)
  • ブラジル
  • アルゼンチン

第10章 中東・アフリカ

• 中東・アフリカの市場規模 (2020-2031)
• 中東・アフリカの主要企業 収益 2024年
• 中東・アフリカの妊娠前遺伝子スクリーニング・サービス 市場規模：タイプ別 (2020-2031)
• 中東・アフリカの妊娠前遺伝子スクリーニング・サービス 市場規模：用途別 (2020-2031)
• 中東・アフリカの投資機会と主な課題
• 中東・アフリカの妊娠前遺伝子スクリーニング・サービス 市場規模：国別
  • 中東・アフリカの収益動向：国別 (2020 VS 2024 VS 2031)
  • 湾岸協力理事会諸国
  • イスラエル
  • エジプト
  • 南アフリカ

第11章 企業プロファイル

• Invitae
• Natera
• Fulgent Genetics
• Myriad Genetics
• Quest Diagnostics
• LabCorp
• GeneDx
• Vitrolife
• Illumina
• BillionToOne
• Juno Genetics
• MedGenome
• 23andMe
• Sonic Genetics
• CEN4GEN
• BGI Genomics
• Berry Genomics
• Anoroad
• KingMed Diagnostics
• CapitalBio Technology

第12章 妊娠前遺伝子スクリーニング・サービス業界チェーン分析

• 妊娠前遺伝子スクリーニング・サービス 産業チェーン
• 上流分析
  • 上流 主要サプライヤー
• 中流分析
• 下流 販売モデルと流通ネットワーク
  • 販売チャネル
  • 卸業者

第13章 妊娠前遺伝子スクリーニング・サービス 市場動向

• 業界動向と進化
• 市場 成長ドライバーと新興の機会
• 市場の課題、リスク、抑制

第14章 主な調査結果 世界の妊娠前遺伝子スクリーニング・サービスの主な市場調査結果

第15章 付録

List of Tables

Table 1. Global Pre-Pregnancy Genetic Screening Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Pre-Pregnancy Genetic Screening Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Pre-Pregnancy Genetic Screening Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Pre-Pregnancy Genetic Screening Service Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Pre-Pregnancy Genetic Screening Service Revenue by Region (2026-2031) & (US$ Million)

Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 7. Global Pre-Pregnancy Genetic Screening Service Revenue by Players (2020-2025) & (US$ Million)

Table 8. Global Pre-Pregnancy Genetic Screening Service Revenue Market Share by Players (2020-2025)

Table 9. Global Key Players'Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 10. Global Pre-Pregnancy Genetic Screening Service by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pre-Pregnancy Genetic Screening Service as of 2024)

Table 11. Global Pre-Pregnancy Genetic Screening Service Average Gross Margin (%) by Player (2020 VS 2024)

Table 12. Global Pre-Pregnancy Genetic Screening Service Companies Headquarters

Table 13. Global Pre-Pregnancy Genetic Screening Service Market Concentration Ratio (CR5 and HHI)

Table 14. Key Market Entrant/Exit (2020-2024) - Drivers & Impact Analysis

Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 16. Global Pre-Pregnancy Genetic Screening Service Revenue by Type (2020-2025) & (US$ Million)

Table 17. Global Pre-Pregnancy Genetic Screening Service Revenue by Type (2026-2031) & (US$ Million)

Table 18. Key Product Attributes and Differentiation

Table 19. Global Pre-Pregnancy Genetic Screening Service Revenue by Application (2020-2025) & (US$ Million)

Table 20. Global Pre-Pregnancy Genetic Screening Service Revenue by Application (2026-2031) & (US$ Million)

Table 21. Pre-Pregnancy Genetic Screening Service High-Growth Sectors Demand CAGR (2024-2031)

Table 22. Top Customers by Region

Table 23. Top Customers by Application

Table 24. North America Pre-Pregnancy Genetic Screening Service Growth Accelerators and Market Barriers

Table 25. North America Pre-Pregnancy Genetic Screening Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 26. Europe Pre-Pregnancy Genetic Screening Service Growth Accelerators and Market Barriers

Table 27. Europe Pre-Pregnancy Genetic Screening Service Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. Asia-Pacific Pre-Pregnancy Genetic Screening Service Growth Accelerators and Market Barriers

Table 29. Asia-Pacific Pre-Pregnancy Genetic Screening Service Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 30. Central and South America Pre-Pregnancy Genetic Screening Service Investment Opportunities and Key Challenges

Table 31. Central and South America Pre-Pregnancy Genetic Screening Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 32. Middle East and Africa Pre-Pregnancy Genetic Screening Service Investment Opportunities and Key Challenges

Table 33. Middle East and Africa Pre-Pregnancy Genetic Screening Service Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 34. Invitae Corporation Information

Table 35. Invitae Description and Major Businesses

Table 36. Invitae Product Features and Attributes

Table 37. Invitae Revenue (US$ Million) and Gross Margin (2020-2025)

Table 38. Invitae Revenue Proportion by Product in 2024

Table 39. Invitae Revenue Proportion by Application in 2024

Table 40. Invitae Revenue Proportion by Geographic Area in 2024

Table 41. Invitae Pre-Pregnancy Genetic Screening Service SWOT Analysis

Table 42. Invitae Recent Developments

Table 43. Natera Corporation Information

Table 44. Natera Description and Major Businesses

Table 45. Natera Product Features and Attributes

Table 46. Natera Revenue (US$ Million) and Gross Margin (2020-2025)

Table 47. Natera Revenue Proportion by Product in 2024

Table 48. Natera Revenue Proportion by Application in 2024

Table 49. Natera Revenue Proportion by Geographic Area in 2024

Table 50. Natera Pre-Pregnancy Genetic Screening Service SWOT Analysis

Table 51. Natera Recent Developments

Table 52. Fulgent Genetics Corporation Information

Table 53. Fulgent Genetics Description and Major Businesses

Table 54. Fulgent Genetics Product Features and Attributes

Table 55. Fulgent Genetics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 56. Fulgent Genetics Revenue Proportion by Product in 2024

Table 57. Fulgent Genetics Revenue Proportion by Application in 2024

Table 58. Fulgent Genetics Revenue Proportion by Geographic Area in 2024

Table 59. Fulgent Genetics Pre-Pregnancy Genetic Screening Service SWOT Analysis

Table 60. Fulgent Genetics Recent Developments

Table 61. Myriad Genetics Corporation Information

Table 62. Myriad Genetics Description and Major Businesses

Table 63. Myriad Genetics Product Features and Attributes

Table 64. Myriad Genetics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 65. Myriad Genetics Revenue Proportion by Product in 2024

Table 66. Myriad Genetics Revenue Proportion by Application in 2024

Table 67. Myriad Genetics Revenue Proportion by Geographic Area in 2024

Table 68. Myriad Genetics Pre-Pregnancy Genetic Screening Service SWOT Analysis

Table 69. Myriad Genetics Recent Developments

Table 70. Quest Diagnostics Corporation Information

Table 71. Quest Diagnostics Description and Major Businesses

Table 72. Quest Diagnostics Product Features and Attributes

Table 73. Quest Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 74. Quest Diagnostics Revenue Proportion by Product in 2024

Table 75. Quest Diagnostics Revenue Proportion by Application in 2024

Table 76. Quest Diagnostics Revenue Proportion by Geographic Area in 2024

Table 77. Quest Diagnostics Pre-Pregnancy Genetic Screening Service SWOT Analysis

Table 78. Quest Diagnostics Recent Developments

Table 79. LabCorp Corporation Information

Table 80. LabCorp Description and Major Businesses

Table 81. LabCorp Product Features and Attributes

Table 82. LabCorp Revenue (US$ Million) and Gross Margin (2020-2025)

Table 83. LabCorp Recent Developments

Table 84. GeneDx Corporation Information

Table 85. GeneDx Description and Major Businesses

Table 86. GeneDx Product Features and Attributes

Table 87. GeneDx Revenue (US$ Million) and Gross Margin (2020-2025)

Table 88. GeneDx Recent Developments

Table 89. Vitrolife Corporation Information

Table 90. Vitrolife Description and Major Businesses

Table 91. Vitrolife Product Features and Attributes

Table 92. Vitrolife Revenue (US$ Million) and Gross Margin (2020-2025)

Table 93. Vitrolife Recent Developments

Table 94. Illumina Corporation Information

Table 95. Illumina Description and Major Businesses

Table 96. Illumina Product Features and Attributes

Table 97. Illumina Revenue (US$ Million) and Gross Margin (2020-2025)

Table 98. Illumina Recent Developments

Table 99. BillionToOne Corporation Information

Table 100. BillionToOne Description and Major Businesses

Table 101. BillionToOne Product Features and Attributes

Table 102. BillionToOne Revenue (US$ Million) and Gross Margin (2020-2025)

Table 103. BillionToOne Recent Developments

Table 104. Juno Genetics Corporation Information

Table 105. Juno Genetics Description and Major Businesses

Table 106. Juno Genetics Product Features and Attributes

Table 107. Juno Genetics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 108. Juno Genetics Recent Developments

Table 109. MedGenome Corporation Information

Table 110. MedGenome Description and Major Businesses

Table 111. MedGenome Product Features and Attributes

Table 112. MedGenome Revenue (US$ Million) and Gross Margin (2020-2025)

Table 113. MedGenome Recent Developments

Table 114. 23andMe Corporation Information

Table 115. 23andMe Description and Major Businesses

Table 116. 23andMe Product Features and Attributes

Table 117. 23andMe Revenue (US$ Million) and Gross Margin (2020-2025)

Table 118. 23andMe Recent Developments

Table 119. Sonic Genetics Corporation Information

Table 120. Sonic Genetics Description and Major Businesses

Table 121. Sonic Genetics Product Features and Attributes

Table 122. Sonic Genetics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 123. Sonic Genetics Recent Developments

Table 124. CEN4GEN Corporation Information

Table 125. CEN4GEN Description and Major Businesses

Table 126. CEN4GEN Product Features and Attributes

Table 127. CEN4GEN Revenue (US$ Million) and Gross Margin (2020-2025)

Table 128. CEN4GEN Recent Developments

Table 129. BGI Genomics Corporation Information

Table 130. BGI Genomics Description and Major Businesses

Table 131. BGI Genomics Product Features and Attributes

Table 132. BGI Genomics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 133. BGI Genomics Recent Developments

Table 134. Berry Genomics Corporation Information

Table 135. Berry Genomics Description and Major Businesses

Table 136. Berry Genomics Product Features and Attributes

Table 137. Berry Genomics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 138. Berry Genomics Recent Developments

Table 139. Anoroad Corporation Information

Table 140. Anoroad Description and Major Businesses

Table 141. Anoroad Product Features and Attributes

Table 142. Anoroad Revenue (US$ Million) and Gross Margin (2020-2025)

Table 143. Anoroad Recent Developments

Table 144. KingMed Diagnostics Corporation Information

Table 145. KingMed Diagnostics Description and Major Businesses

Table 146. KingMed Diagnostics Product Features and Attributes

Table 147. KingMed Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)

Table 148. KingMed Diagnostics Recent Developments

Table 149. CapitalBio Technology Corporation Information

Table 150. CapitalBio Technology Description and Major Businesses

Table 151. CapitalBio Technology Product Features and Attributes

Table 152. CapitalBio Technology Revenue (US$ Million) and Gross Margin (2020-2025)

Table 153. CapitalBio Technology Recent Developments

Table 154. Raw Materials Key Suppliers

Table 155. Distributors List

Table 156. Market Trends and Market Evolution

Table 157. Market Drivers and Opportunities

Table 158. Market Challenges, Risks, and Restraints

Table 159. Research Programs/Design for This Report

Table 160. Key Data Information from Secondary Sources

Table 161. Key Data Information from Primary Sources

List of Figures

Figure 1. Pre-Pregnancy Genetic Screening Service Product Picture

Figure 2. Global Pre-Pregnancy Genetic Screening Service Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Single Disease Screening Product Picture

Figure 4. Whole Genome Screening Product Picture

Figure 5. Global Pre-Pregnancy Genetic Screening Service Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Medical and Health Institutions

Figure 7. Research and Educational Institutions

Figure 8. Others

Figure 9. Pre-Pregnancy Genetic Screening Service Report Years Considered

Figure 10. Global Pre-Pregnancy Genetic Screening Service Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 12. Global Pre-Pregnancy Genetic Screening Service Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Pre-Pregnancy Genetic Screening Service Revenue Market Share by Region (2020-2031)

Figure 14. Global Pre-Pregnancy Genetic Screening Service Revenue Market Share Ranking (2024)

Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 16. Single Disease Screening Revenue Market Share by Player in 2024

Figure 17. Whole Genome Screening Revenue Market Share by Player in 2024

Figure 18. Global Pre-Pregnancy Genetic Screening Service Revenue Market Share by Type (2020-2031)

Figure 19. Global Pre-Pregnancy Genetic Screening Service Revenue Market Share by Application (2020-2031)

Figure 20. North America Pre-Pregnancy Genetic Screening Service Revenue YoY (2020-2031) & (US$ Million)

Figure 21. North America Top 5 Players Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) in 2024

Figure 22. North America Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) by Type (2020 - 2031)

Figure 23. North America Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) by Application (2020-2031)

Figure 24. US Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 25. Canada Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 26. Mexico Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 27. Europe Pre-Pregnancy Genetic Screening Service Revenue YoY (2020-2031) & (US$ Million)

Figure 28. Europe Top 5 Players Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) in 2024

Figure 29. Europe Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) by Type (2020-2031)

Figure 30. Europe Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) by Application (2020-2031)

Figure 31. Germany Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 32. France Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 33. U.K. Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 34. Italy Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 35. Russia Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Pre-Pregnancy Genetic Screening Service Revenue YoY (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Top 8 Players Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) in 2024

Figure 38. Asia-Pacific Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) by Type (2020-2031)

Figure 39. Asia-Pacific Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) by Application (2020-2031)

Figure 40. Indonesia Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 41. Japan Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 42. South Korea Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 43. Australia Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 44. India Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 45. Indonesia Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 46. Vietnam Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 47. Malaysia Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 48. Philippines Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 49. Singapore Pre-Pregnancy Genetic Screening Service Revenue (2020-2031) & (US$ Million)

Figure 50. Central and South America Pre-Pregnancy Genetic Screening Service Revenue YoY (2020-2031) & (US$ Million)

Figure 51. Central and South America Top 5 Players Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) in 2024

Figure 52. Central and South America Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) by Type (2020-2031)

Figure 53. Central and South America Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) by Application (2020-2031)

Figure 54. Brazil Pre-Pregnancy Genetic Screening Service Revenue (2020-2025) & (US$ Million)

Figure 55. Argentina Pre-Pregnancy Genetic Screening Service Revenue (2020-2025) & (US$ Million)

Figure 56. Middle East and Africa Pre-Pregnancy Genetic Screening Service Revenue YoY (2020-2031) & (US$ Million)

Figure 57. Middle East and Africa Top 5 Players Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) in 2024

Figure 58. South America Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) by Type (2020-2031)

Figure 59. Middle East and Africa Pre-Pregnancy Genetic Screening Service Revenue (US$ Million) by Application (2020-2031)

Figure 60. GCC Countries Pre-Pregnancy Genetic Screening Service Revenue (2020-2025) & (US$ Million)

Figure 61. Israel Pre-Pregnancy Genetic Screening Service Revenue (2020-2025) & (US$ Million)

Figure 62. Egypt Pre-Pregnancy Genetic Screening Service Revenue (2020-2025) & (US$ Million)

Figure 63. South Africa Pre-Pregnancy Genetic Screening Service Revenue (2020-2025) & (US$ Million)

Figure 64. Pre-Pregnancy Genetic Screening Service Industry Chain Mapping

Figure 65. Channels of Distribution (Direct Vs Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

This research report focuses on the Pre-Pregnancy Genetic Screening Service Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Introduction to Pre-Pregnancy Genetic Screening Service: Definition, Properties, and Key Attributes
• 1.2 Market Segmentation by Type
  • 1.2.1 Global Pre-Pregnancy Genetic Screening Service Market Size by Type, 2020 VS 2024 VS 2031
  • 1.2.2 Single Disease Screening
  • 1.2.3 Whole Genome Screening
• 1.3 Market Segmentation by Application
  • 1.3.1 Global Pre-Pregnancy Genetic Screening Service Market Size by Application, 2020 VS 2024 VS 2031
  • 1.3.2 Medical and Health Institutions
  • 1.3.3 Research and Educational Institutions
  • 1.3.4 Others
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global Pre-Pregnancy Genetic Screening Service Revenue Estimates and Forecasts 2020-2031
• 2.2 Global Pre-Pregnancy Genetic Screening Service Revenue by Region
  • 2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
  • 2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
  • 2.2.3 Global Revenue Market Share by Region (2020-2031)
  • 2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competition by Players

• 3.1 Global Pre-Pregnancy Genetic Screening Service Player Revenue Rankings and Profitability
  • 3.1.1 Global Revenue (Value) by Players (2020-2025)
  • 3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
  • 3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
  • 3.1.4 Gross Margin by Top Player (2020 VS 2024)
• 3.2 Global Pre-Pregnancy Genetic Screening Service Companies Headquarters and Service Footprint
• 3.3 Main Product Type Market Size by Players
  • 3.3.1 Single Disease Screening Market Size by Players
  • 3.3.2 Whole Genome Screening Market Size by Players
• 3.4 Global Pre-Pregnancy Genetic Screening Service Market Concentration and Dynamics
  • 3.4.1 Global Market Concentration (CR5 and HHI)
  • 3.4.2 Entrant/Exit Impact Analysis
  • 3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Global Product Segmentation Analysis

• 4.1 Global Pre-Pregnancy Genetic Screening Service Revenue Trends by Type
  • 4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
  • 4.1.2 Global Revenue Market Share by Type (2020-2031)
• 4.2 Key Product Attributes and Differentiation
• 4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
  • 4.3.1 High-Growth Niches and Adoption Drivers
  • 4.3.2 Profitability Hotspots and Cost Drivers
  • 4.3.3 Substitution Threats

5 Global Downstream Application Analysis

• 5.1 Global Pre-Pregnancy Genetic Screening Service Revenue by Application
  • 5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
  • 5.1.2 Revenue Market Share by Application (2020-2031)
  • 5.1.3 High-Growth Application Identification
  • 5.1.4 Emerging Application Case Studies
• 5.2 Downstream Customer Analysis
  • 5.2.1 Top Customers by Region
  • 5.2.2 Top Customers by Application

6 North America

• 6.1 North America Market Size (2020-2031)
• 6.2 North America Key Players Revenue in 2024
• 6.3 North America Pre-Pregnancy Genetic Screening Service Market Size by Type (2020-2031)
• 6.4 North America Pre-Pregnancy Genetic Screening Service Market Size by Application (2020-2031)
• 6.5 North America Growth Accelerators and Market Barriers
• 6.6 North America Pre-Pregnancy Genetic Screening Service Market Size by Country
  • 6.6.1 North America Revenue Trends by Country
  • 6.6.2 US
  • 6.6.3 Canada
  • 6.6.4 Mexico

7 Europe

• 7.1 Europe Market Size (2020-2031)
• 7.2 Europe Key Players Revenue in 2024
• 7.3 Europe Pre-Pregnancy Genetic Screening Service Market Size by Type (2020-2031)
• 7.4 Europe Pre-Pregnancy Genetic Screening Service Market Size by Application (2020-2031)
• 7.5 Europe Growth Accelerators and Market Barriers
• 7.6 Europe Pre-Pregnancy Genetic Screening Service Market Size by Country
  • 7.6.1 Europe Revenue Trends by Country
  • 7.6.2 Germany
  • 7.6.3 France
  • 7.6.4 U.K.
  • 7.6.5 Italy
  • 7.6.6 Russia

8 Asia-Pacific

• 8.1 Asia-Pacific Market Size (2020-2031)
• 8.2 Asia-Pacific Key Players Revenue in 2024
• 8.3 Asia-Pacific Pre-Pregnancy Genetic Screening Service Market Size by Type (2020-2031)
• 8.4 Asia-Pacific Pre-Pregnancy Genetic Screening Service Market Size by Application (2020-2031)
• 8.5 Asia-Pacific Growth Accelerators and Market Barriers
• 8.6 Asia-Pacific Pre-Pregnancy Genetic Screening Service Market Size by Region
  • 8.6.1 Asia-Pacific Revenue Trends by Region
• 8.7 China
• 8.8 Japan
• 8.9 South Korea
• 8.10 Australia
• 8.11 India
• 8.12 Southeast Asia
  • 8.12.1 Indonesia
  • 8.12.2 Vietnam
  • 8.12.3 Malaysia
  • 8.12.4 Philippines
  • 8.12.5 Singapore

9 Central and South America

• 9.1 Central and South America Market Size (2020-2031)
• 9.2 Central and South America Key Players Revenue in 2024
• 9.3 Central and South America Pre-Pregnancy Genetic Screening Service Market Size by Type (2020-2031)
• 9.4 Central and South America Pre-Pregnancy Genetic Screening Service Market Size by Application (2020-2031)
• 9.5 Central and South America Investment Opportunities and Key Challenges
• 9.6 Central and South America Pre-Pregnancy Genetic Screening Service Market Size by Country
  • 9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
  • 9.6.2 Brazil
  • 9.6.3 Argentina

10 Middle East and Africa

• 10.1 Middle East and Africa Market Size (2020-2031)
• 10.2 Middle East and Africa Key Players Revenue in 2024
• 10.3 Middle East and Africa Pre-Pregnancy Genetic Screening Service Market Size by Type (2020-2031)
• 10.4 Middle East and Africa Pre-Pregnancy Genetic Screening Service Market Size by Application (2020-2031)
• 10.5 Middle East and Africa Investment Opportunities and Key Challenges
• 10.6 Middle East and Africa Pre-Pregnancy Genetic Screening Service Market Size by Country
  • 10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
  • 10.6.2 GCC Countries
  • 10.6.3 Israel
  • 10.6.4 Egypt
  • 10.6.5 South Africa

11 Corporate Profile

• 11.1 Invitae
  • 11.1.1 Invitae Corporation Information
  • 11.1.2 Invitae Business Overview
  • 11.1.3 Invitae Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.1.4 Invitae Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.1.5 Invitae Pre-Pregnancy Genetic Screening Service Revenue by Product in 2024
  • 11.1.6 Invitae Pre-Pregnancy Genetic Screening Service Revenue by Application in 2024
  • 11.1.7 Invitae Pre-Pregnancy Genetic Screening Service Revenue by Geographic Area in 2024
  • 11.1.8 Invitae Pre-Pregnancy Genetic Screening Service SWOT Analysis
  • 11.1.9 Invitae Recent Developments
• 11.2 Natera
  • 11.2.1 Natera Corporation Information
  • 11.2.2 Natera Business Overview
  • 11.2.3 Natera Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.2.4 Natera Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.2.5 Natera Pre-Pregnancy Genetic Screening Service Revenue by Product in 2024
  • 11.2.6 Natera Pre-Pregnancy Genetic Screening Service Revenue by Application in 2024
  • 11.2.7 Natera Pre-Pregnancy Genetic Screening Service Revenue by Geographic Area in 2024
  • 11.2.8 Natera Pre-Pregnancy Genetic Screening Service SWOT Analysis
  • 11.2.9 Natera Recent Developments
• 11.3 Fulgent Genetics
  • 11.3.1 Fulgent Genetics Corporation Information
  • 11.3.2 Fulgent Genetics Business Overview
  • 11.3.3 Fulgent Genetics Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.3.4 Fulgent Genetics Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.3.5 Fulgent Genetics Pre-Pregnancy Genetic Screening Service Revenue by Product in 2024
  • 11.3.6 Fulgent Genetics Pre-Pregnancy Genetic Screening Service Revenue by Application in 2024
  • 11.3.7 Fulgent Genetics Pre-Pregnancy Genetic Screening Service Revenue by Geographic Area in 2024
  • 11.3.8 Fulgent Genetics Pre-Pregnancy Genetic Screening Service SWOT Analysis
  • 11.3.9 Fulgent Genetics Recent Developments
• 11.4 Myriad Genetics
  • 11.4.1 Myriad Genetics Corporation Information
  • 11.4.2 Myriad Genetics Business Overview
  • 11.4.3 Myriad Genetics Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.4.4 Myriad Genetics Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.4.5 Myriad Genetics Pre-Pregnancy Genetic Screening Service Revenue by Product in 2024
  • 11.4.6 Myriad Genetics Pre-Pregnancy Genetic Screening Service Revenue by Application in 2024
  • 11.4.7 Myriad Genetics Pre-Pregnancy Genetic Screening Service Revenue by Geographic Area in 2024
  • 11.4.8 Myriad Genetics Pre-Pregnancy Genetic Screening Service SWOT Analysis
  • 11.4.9 Myriad Genetics Recent Developments
• 11.5 Quest Diagnostics
  • 11.5.1 Quest Diagnostics Corporation Information
  • 11.5.2 Quest Diagnostics Business Overview
  • 11.5.3 Quest Diagnostics Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.5.4 Quest Diagnostics Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.5.5 Quest Diagnostics Pre-Pregnancy Genetic Screening Service Revenue by Product in 2024
  • 11.5.6 Quest Diagnostics Pre-Pregnancy Genetic Screening Service Revenue by Application in 2024
  • 11.5.7 Quest Diagnostics Pre-Pregnancy Genetic Screening Service Revenue by Geographic Area in 2024
  • 11.5.8 Quest Diagnostics Pre-Pregnancy Genetic Screening Service SWOT Analysis
  • 11.5.9 Quest Diagnostics Recent Developments
• 11.6 LabCorp
  • 11.6.1 LabCorp Corporation Information
  • 11.6.2 LabCorp Business Overview
  • 11.6.3 LabCorp Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.6.4 LabCorp Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.6.5 LabCorp Recent Developments
• 11.7 GeneDx
  • 11.7.1 GeneDx Corporation Information
  • 11.7.2 GeneDx Business Overview
  • 11.7.3 GeneDx Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.7.4 GeneDx Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.7.5 GeneDx Recent Developments
• 11.8 Vitrolife
  • 11.8.1 Vitrolife Corporation Information
  • 11.8.2 Vitrolife Business Overview
  • 11.8.3 Vitrolife Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.8.4 Vitrolife Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.8.5 Vitrolife Recent Developments
• 11.9 Illumina
  • 11.9.1 Illumina Corporation Information
  • 11.9.2 Illumina Business Overview
  • 11.9.3 Illumina Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.9.4 Illumina Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.9.5 Illumina Recent Developments
• 11.10 BillionToOne
  • 11.10.1 BillionToOne Corporation Information
  • 11.10.2 BillionToOne Business Overview
  • 11.10.3 BillionToOne Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.10.4 BillionToOne Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.10.5 Company Ten Recent Developments
• 11.11 Juno Genetics
  • 11.11.1 Juno Genetics Corporation Information
  • 11.11.2 Juno Genetics Business Overview
  • 11.11.3 Juno Genetics Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.11.4 Juno Genetics Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.11.5 Juno Genetics Recent Developments
• 11.12 MedGenome
  • 11.12.1 MedGenome Corporation Information
  • 11.12.2 MedGenome Business Overview
  • 11.12.3 MedGenome Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.12.4 MedGenome Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.12.5 MedGenome Recent Developments
• 11.13 23andMe
  • 11.13.1 23andMe Corporation Information
  • 11.13.2 23andMe Business Overview
  • 11.13.3 23andMe Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.13.4 23andMe Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.13.5 23andMe Recent Developments
• 11.14 Sonic Genetics
  • 11.14.1 Sonic Genetics Corporation Information
  • 11.14.2 Sonic Genetics Business Overview
  • 11.14.3 Sonic Genetics Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.14.4 Sonic Genetics Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.14.5 Sonic Genetics Recent Developments
• 11.15 CEN4GEN
  • 11.15.1 CEN4GEN Corporation Information
  • 11.15.2 CEN4GEN Business Overview
  • 11.15.3 CEN4GEN Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.15.4 CEN4GEN Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.15.5 CEN4GEN Recent Developments
• 11.16 BGI Genomics
  • 11.16.1 BGI Genomics Corporation Information
  • 11.16.2 BGI Genomics Business Overview
  • 11.16.3 BGI Genomics Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.16.4 BGI Genomics Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.16.5 BGI Genomics Recent Developments
• 11.17 Berry Genomics
  • 11.17.1 Berry Genomics Corporation Information
  • 11.17.2 Berry Genomics Business Overview
  • 11.17.3 Berry Genomics Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.17.4 Berry Genomics Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.17.5 Berry Genomics Recent Developments
• 11.18 Anoroad
  • 11.18.1 Anoroad Corporation Information
  • 11.18.2 Anoroad Business Overview
  • 11.18.3 Anoroad Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.18.4 Anoroad Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.18.5 Anoroad Recent Developments
• 11.19 KingMed Diagnostics
  • 11.19.1 KingMed Diagnostics Corporation Information
  • 11.19.2 KingMed Diagnostics Business Overview
  • 11.19.3 KingMed Diagnostics Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.19.4 KingMed Diagnostics Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.19.5 KingMed Diagnostics Recent Developments
• 11.20 CapitalBio Technology
  • 11.20.1 CapitalBio Technology Corporation Information
  • 11.20.2 CapitalBio Technology Business Overview
  • 11.20.3 CapitalBio Technology Pre-Pregnancy Genetic Screening Service Product Features and Attributes
  • 11.20.4 CapitalBio Technology Pre-Pregnancy Genetic Screening Service Revenue and Gross Margin (2020-2025)
  • 11.20.5 CapitalBio Technology Recent Developments

12 Pre-Pregnancy Genetic Screening ServiceIndustry Chain Analysis

• 12.1 Pre-Pregnancy Genetic Screening Service Industry Chain
• 12.2 Upstream Analysis
  • 12.2.1 Upstream Key Suppliers
• 12.3 Middlestream Analysis
• 12.4 Downstream Sales Model and Distribution Networks
  • 12.4.1 Sales Channels
  • 12.4.2 Distributors

13 Pre-Pregnancy Genetic Screening Service Market Dynamics

• 13.1 Industry Trends and Evolution
• 13.2 Market Growth Drivers and Emerging Opportunities
• 13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Pre-Pregnancy Genetic Screening Service Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Author Details